China Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>CB</div>
CBPO -- USA Stock  

USD 111.76  1.95  1.78%

China Biologic Products is scheduled to announce its earnings today. The next earnings report is expected on the 11th of November 2020. China Biologic Invested Capital Average is quite stable at the moment as compared to the past year. The company's current value of Invested Capital Average is estimated at 807.65 Million. Market Capitalization is expected to rise to about 4.9 B this year, although the value of Net Income Per Employee will most likely fall to about 49.4 K. As many of us are excited about healthcare space, it is fair to outline China Biologic Products as a unique alternative.
Published over a month ago
View all stories for China Biologic | View All Stories
How much will China Biologic owe in September?
China Biologic Debt to Equity Ratio is quite stable at the moment as compared to the past year. The company's current value of Debt to Equity Ratio is estimated at 0.09. Average Equity is expected to rise to about 1.8 B this year, although the value of Long Term Debt to Equity will most likely fall to 0.16. This firm has a current ratio of 10.3, suggesting that it is liquid enough and is able to pay its financial obligations when due.
China Biologic financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of China Biologic, including all of China Biologic's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of China Biologic assets, the company is considered highly leveraged. Understanding the composition and structure of overall China Biologic debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding China Total Debt

China Biologic Products liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. China Biologic Products has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on China Biologic balance sheet include debt obligations and money owed to different China Biologic vendors, workers, and loan providers. Below is the chart of China main long-term debt accounts currently reported on its balance sheet.
You can use China Biologic Products financial leverage analysis tool to get a better grip on understanding its financial position

How important is China Biologic's Liquidity

China Biologic financial leverage refers to using borrowed capital as a funding source to finance China Biologic Products ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. China Biologic financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between China Biologic's total debt and its cash.

Exercise or conversion by Kuo Yuyun Tristan of 5000 shares of China Biologic subject to Rule 16b-3

Legal trades by China Biologic insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
China Biologic Products insider trading alert for exercise of non-qualified stock option (right to buy) by Kuo Yuyun Tristan, CFO, on 15th of June 2020. This event was filed by China Biologic Products H with SEC on 2011-12-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down China Biologic Indicators

The company reported the previous year's revenue of 536.55 M. Net Income was 152.81 M with profit before overhead, payroll, taxes, and interest of 329.08 M.

Liabilities Breakdown

41.2 M
Tax Liabilities
110.5 M
Current Liabilities
38.5 M
Long-Term Liabilities
Deposit Liabilities3.46 Million
Total Liabilities148.98 Million
Current Liabilities110.51 Million
Long-Term Liabilities38.47 Million
Tax Liabilities41.23 Million

Will China continue to rise?

Coefficient of variation is down to 6102.61. It may entail a possible volatility slide. China Biologic Products has low volatility with Treynor Ratio of -0.04, Maximum Drawdown of 6.64 and kurtosis of 3.64. However, we advice all investors to further analyze China Biologic Products to make certain all market information is desiminated and is consistent with the current expectations about China Biologic upside potential.

Our Bottom Line On China Biologic Products

When is the right time to buy or sell China Biologic Products? Buying stocks such as China Biologic isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of China nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to China Biologic.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of China Biologic Products. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com